Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Associated Therapies
-
Clinical Trials
Related News

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

First Posted Date
2024-12-04
Last Posted Date
2024-12-05
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
300
Registration Number
NCT06715007
Locations
🇨🇳

the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Early Phase 1
Recruiting
Conditions
Interaction
Interventions
Drug: Cannabidiol in the form of hemp
Drug: Clopidogrel
First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Washington State University
Target Recruit Count
24
Registration Number
NCT06692933
Locations
🇺🇸

Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States

Clopidogrel Vs. Aspirin in Patients with S. Aureus Bacteremia

First Posted Date
2024-10-21
Last Posted Date
2024-10-21
Lead Sponsor
Todd C. Lee MD MPH FIDSA
Target Recruit Count
300
Registration Number
NCT06650488
Locations
🇨🇦

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada

Study of Tiprogrel in the Treatment of High-risk Patients With Acute Ischemic Cerebrovascular Events.

Phase 2
Not yet recruiting
Conditions
Ischemic Stroke
Interventions
Drug: Tipidogrel
Drug: Clopidogrel
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Tianjin Institute of Pharmaceutical Research Co., Ltd
Target Recruit Count
600
Registration Number
NCT06601127
Locations
🇨🇳

Beijing Tiantan Hosptial, Capital Medical University, Beijing, China

Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3
Recruiting
Conditions
Ischemic Stroke
Interventions
Drug: Ticagrelor 90 MG
Drug: Clopidogrel
First Posted Date
2024-09-11
Last Posted Date
2024-09-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
900
Registration Number
NCT06591338
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Phase 3
Recruiting
Conditions
Ischemic Stroke
Interventions
Drug: Ticagrelor 90 MG
Drug: Clopidogrel
First Posted Date
2024-09-11
Last Posted Date
2024-09-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
900
Registration Number
NCT06591312
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3
Recruiting
Conditions
Ischemic Stroke
Interventions
Drug: Cilostazol 100 MG
Drug: Clopidogrel
First Posted Date
2024-09-11
Last Posted Date
2024-09-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
870
Registration Number
NCT06591351
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
Tianjin Institute of Pharmaceutical Research Co., Ltd
Target Recruit Count
14
Registration Number
NCT06584812
Locations
🇨🇳

Beijing Tiantan Hosptial, Capital Medical University, Beijing, China

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

First Posted Date
2024-08-29
Last Posted Date
2024-10-01
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
1000
Registration Number
NCT06577519
Locations
🇨🇳

General Hospital of Northern Theater Command of Chinese PLA, Shenyang, Liaoning, China

Cilostazol and Aspirin in Stroke and TIA

Phase 4
Completed
Conditions
TIA
Ischemic Stroke
Interventions
Drug: Clopidogrel
Drug: Cilostazol
First Posted Date
2024-07-26
Last Posted Date
2024-08-06
Lead Sponsor
Incheon St.Mary's Hospital
Target Recruit Count
378
Registration Number
NCT06522113
Locations
🇰🇷

The Catholic university of korea, Incheon St. Mary's hospital, Incheon, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy